Chimeric antigen receptor T cell technology (CAR-T) and T cell receptor chimeric T cell (TCR-T), as the two latest immune cell technologies of ACT adoptive cell therapy, are widely popular and studied because it can express specific receptors for target recognition of specific cells such as tumor cells, from basic immunology research to clinical application. Based on synthetic biology, immunology, genetic modification techniques, it is possible to synthesize modified, functional and enhanced T cells. CD19 antigen specific CAR-T cells have been shown to have sustained disease remission effect in clinical trials of B cell leukemia and lymphoma. Due to the superior performance and broad application prospects of CAR-T/TCR-T technology, it enters the current fierce arena in the pharmaceutical industry to fight against traditional industry.
In this article, Creative Biolabs explores the current opportunities for adoptive cell therapy, like CAR-T/TCR-T technology.
CAR/TCR clinical application prospects:
1.HIV-1 infection or other chronic infectious diseases
There are cases that CAR-T cells are able to survive in HIV-1 infected AIDS patients. Recent studies have also found that targeted CD8+ CTL cells are capable of clearing the virus pool in HIV-1 infected mice. This suggests that genetically modified TCR engineered t cells may be useful in the treatment of HIV-1 infections or other chronic infections.
2.The transformation of regulatory Tregs cells for the treatment of autoimmune diseases
By modulating or controlling Tregs cells, such as adoptive re-infusion Tregs cells, some immune side effects, such as autoimmune diseases and organ transplant rejection, are reduced. For example, we use CAR technology to target myelin basic protein modified mouse Tregs cells, it can reduce inflammatory reaction of brain tissue, reducing autoimmune encephalitis. The same technique is also intended for the treatment of colitis or pancreatitis.
3. Optimization of CAR Technology
CAR technology has evolved over the past twenty years from the first generation of MHC-I restriction CAR-T to the second generation of CD28 or 4-1BB signaling region antigens. The latest research shows that the CAR-T cell of the gene CD28 signaling peptide accelerates depletion of T cells, whereas CAR-T cells based on 4-1BB signaling peptide antigens can lower T cell consumption. Therefore, further optimization of CAR technology is to extend the CAR-T cell effect time in vivo.
Company Name: CAR-T
Contact Person: Bella Smith
Address:45-1 Ramsey Road
Country: United States